Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tasquinimod - Active Biotech

Drug Profile

Tasquinimod - Active Biotech

Alternative Names: ABR-215050; TASQ

Latest Information Update: 03 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Active Biotech
  • Developer Active Biotech; Ipsen; University of Pennsylvania
  • Class Amides; Antineoplastics; Fluorinated hydrocarbons; Quinolines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Calgranulin B modulators; Immunomodulators; Thrombospondin 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Myelofibrosis
  • New Molecular Entity Yes
  • Available For Licensing Yes - Multiple myeloma

Highest Development Phases

  • Phase I/II Multiple myeloma
  • Phase I Myelofibrosis
  • Preclinical Myelodysplastic syndromes
  • Discontinued Gastric cancer; Liver cancer; Ovarian cancer; Prostate cancer; Renal cancer

Most Recent Events

  • 22 Dec 2023 Active Biotech plans a phase II proof-of-concept trial for Myelofibrosis in Germany and Netherlands in Q3 2024
  • 22 Dec 2023 Active Biotech plans a phase II proof-of-concept trial for Myelofibrosis in USA in mid 2024
  • 22 Dec 2023 Active Biotech announces intention to file a regulatory application for myelofibrosis
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top